Study of CYR-064 Versus Placebo in Patients.

NCT06019000 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2026-02-18

No results posted yet for this study

Summary

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Conditions

  • Hyposmia

Interventions

COMBINATION_PRODUCT

CYR-064

CYR-064 is a nasal solution.

Sponsors & Collaborators

  • Cyrano Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Mas Takashima, MD · The Methodist Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-26
Primary Completion
2025-11-11
Completion
2025-11-21
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06019000 on ClinicalTrials.gov